Please use this identifier to cite or link to this item:
Title: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
Austin Authors: Charles, Patrick G P ;Ward, Peter B;Johnson, Paul D R ;Howden, Benjamin P ;Grayson, M Lindsay 
Affiliation: Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 12-Jan-2004
Publication information: Clinical Infectious Diseases 2004; 38(3): 448-51
Abstract: We assessed all episodes of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia at our hospital during a 12-month period (n=53) and compared those due to heterogeneous vancomycin-intermediate S. aureus (hVISA; n = 5, 9.4%) with those due to vancomycin-susceptible MRSA (n=48). Patients with hVISA bacteremia were more likely to have high bacterial load infections (P=.001), vancomycin treatment failure (persistent fever and bacteremia for >7 days after the start of therapy; P<.001), and initially low serum vancomycin levels (P=.006). These clinical markers of hVISA bacteremia may help focus diagnostic efforts and treatment.
Gov't Doc #: 14727222
DOI: 10.1086/381093
Type: Journal Article
Subjects: Anti-Bacterial Agents.pharmacology.therapeutic use
Bacteremia.drug therapy.microbiology
Drug Resistance, Bacterial
Methicillin Resistance
Staphylococcal Infections.drug therapy.microbiology
Staphylococcus aureus.drug effects
Vancomycin.pharmacology.therapeutic use
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 25, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.